These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22383073)

  • 1. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.
    Burton BK; Giugliani R
    Eur J Pediatr; 2012 Apr; 171(4):631-9. PubMed ID: 22383073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.
    Scarpa M; Almássy Z; Beck M; Bodamer O; Bruce IA; De Meirleir L; Guffon N; Guillén-Navarro E; Hensman P; Jones S; Kamin W; Kampmann C; Lampe C; Lavery CA; Teles EL; Link B; Lund AM; Malm G; Pitz S; Rothera M; Stewart C; Tylki-Szymańska A; van der Ploeg A; Walker R; Zeman J; Wraith JE;
    Orphanet J Rare Dis; 2011 Nov; 6():72. PubMed ID: 22059643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.
    Jurecka A; Krumina Z; Żuber Z; Różdżyńska-Świątkowska A; Kłoska A; Czartoryska B; Tylki-Szymańska A
    Am J Med Genet A; 2012 Feb; 158A(2):450-4. PubMed ID: 22246721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).
    Martin R; Beck M; Eng C; Giugliani R; Harmatz P; Muñoz V; Muenzer J
    Pediatrics; 2008 Feb; 121(2):e377-86. PubMed ID: 18245410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases.
    Sohn YB; Choi EW; Kim SJ; Park SW; Kim SH; Cho SY; Jeong SI; Huh J; Kang IS; Lee HJ; Paik KH; Jin DK
    Am J Med Genet A; 2012 Jan; 158A(1):90-6. PubMed ID: 22105882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary management of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Escolar ML; Giugliani R; Guffon NH; Harmatz P; Kamin W; Kampmann C; Koseoglu ST; Link B; Martin RA; Molter DW; Muñoz Rojas MV; Ogilvie JW; Parini R; Ramaswami U; Scarpa M; Schwartz IV; Wood RE; Wraith E
    Pediatrics; 2009 Dec; 124(6):e1228-39. PubMed ID: 19901005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome.
    Julien DC; Woolgar K; Pollard L; Miller H; Desai A; Lindstrom K; Kishnani PS
    Front Immunol; 2020; 11():1000. PubMed ID: 32508845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients.
    Chkioua L; Grissa O; Leban N; Gribaa M; Boudabous H; Turkia HB; Ferchichi S; Tebib N; Laradi S
    BMC Med Genet; 2020 May; 21(1):111. PubMed ID: 32448126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group].
    Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P;
    Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500
    [No Abstract]   [Full Text] [Related]  

  • 13. Mucopolysaccharidosis type II (Hunter's syndrome) in Taiwan.
    Su PH; Hwu WL; Chiang SC; Chiu PC; Lin SJ; Shu SG; Wang TR
    J Formos Med Assoc; 1998 Mar; 97(3):186-90. PubMed ID: 9549269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hunter Syndrome: Is It Time to Make It Part of Newborn Screening?
    Joseph R; DiCesare EB; Miller A
    Adv Neonatal Care; 2018 Dec; 18(6):480-487. PubMed ID: 30499826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hunter syndrome follow-up after 1 year of enzyme-replacement therapy.
    Puiu M; Chirita-Emandi A; Dumitriu S; Arghirescu S
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23307460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the behavioural manifestations of Hunter syndrome.
    Roberts J; Stewart C; Kearney S
    Br J Nurs; 2016 Jan 14-27; 25(1):22, 24, 26-30. PubMed ID: 26768041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.